glp1ledger

What Is Wegovy? Novo Nordisk's Semaglutide Brand, Its Four Approved Uses and Its Five Forms, From FDA's Records

Wegovy is Novo Nordisk's brand of semaglutide — the same molecule as Ozempic — approved for weight management, heart-attack and stroke risk reduction, and a form of fatty-liver disease. It now comes as pens, a multi-dose pen, syringes, a 7.2 mg HD pen and tablets, and the injection and the tablet are not approved for the same things.

Ronald R · Edited by Caroline S · Published 2026-10-04 · Updated 2026-11-17

Illustration: An unbranded gray cylindrical pen-like object on sage green linen in natural light.
Illustration

Wegovy is Novo Nordisk's brand of semaglutide for weight and weight-related disease. It contains exactly the same molecule as Ozempic, sold under a separate label with separate strengths and separate approved uses — which is why the two are priced, covered and prescribed differently. Five years after its first approval it is no longer one product: FDA's register now lists sixteen Wegovy presentations across pens, syringes, a multi-dose pen and tablets, and the injection and the tablet are not approved for the same things.

This page is built from the Wegovy prescribing information revised in June 2026 (read on DailyMed), FDA's Drugs@FDA approval records and letters, and the Orange Book product file, read on 4 October 2026; the approval history and the label's version record were re-read on 17 November 2026.

Four approved uses, and which form carries each

Approved use Injection Tablets Added
Adults: losing weight and keeping it off, at a BMI in the obesity range or overweight plus a weight-related illness ✓ ✓ first approval, 4 June 2021
Weight reduction, children aged 12 and older with obesity ✓ — 23 December 2022
Adults who already have heart disease and carry excess weight: fewer major heart events (death from heart causes, heart attack, stroke) ✓ ✓ 8 March 2024
Noncirrhotic MASH (formerly NASH) with moderate to advanced fibrosis, F2–F3, in adults — accelerated approval ✓ — 15 August 2025

Uses paraphrased from the June 2026 label (section 1); the dates come from FDA letters approving supplements 5, 11 and 24 to the injection application, and from the tablet application's first approval. The label attaches each use to a lower-calorie diet and more physical activity.

Two details in that table are easy to miss. The MASH use is provisional: the label states that continued approval "may be contingent upon the verification and description of clinical benefit in a confirmatory trial". The liver record is on GLP-1 drugs for fatty liver. And the tablets are adult-only and carry no liver indication, so "Wegovy is approved for X" can be true of the pen and false of the pill. What the adolescent trial behind the 12-and-older use recorded, beside the other GLP-1 approvals for young people, is on GLP-1 drugs for teens. How much weight people lost in each trial behind the weight indication, from STEP 1 to the 7.2 mg STEP UP studies, is tabled on Wegovy weight loss results.

How Wegovy's weight results compare with tirzepatide's is on Zepbound vs Wegovy, and what the tablet's trial and users report is on the Wegovy pill review.

What semaglutide is, in the label's words

The label calls semaglutide "a GLP-1 analogue with 94% sequence homology to human GLP-1". Three engineering changes make it a weekly drug rather than a hormone that lasts minutes, and the label names each: a change at position 8 to resist the enzyme DPP-4, a fatty-acid chain (a "C18 fatty di-acid") attached at position 26 so that it binds to albumin in the blood — "the main protraction mechanism" — and a minor change at position 34 so only one fatty acid attaches. The peptide backbone "is produced by yeast fermentation". Its molecular weight is 4,113.58 g/mol.

On how it acts, the label is brief: the drug switches on the same receptor the body's own GLP-1 uses, that hormone helps set hunger and how much is eaten, and the receptor is present in the parts of the brain that govern appetite. The label is equally direct about the limits — "the exact mechanism of semaglutide in CV risk reduction in adults has not been established", and in MASH it "is not fully understood". The broader biology is on how GLP-1 works.

Five forms, and when each arrived

Form Strengths Listed by FDA
Single-dose pen 0.25, 0.5, 1, 1.7, 2.4 mg 4 June 2021
Tablets (once daily) 1.5, 4, 9, 25 mg 22 December 2025
Wegovy HD single-dose pen 7.2 mg 19 March 2026
Further 0.25–2.4 mg presentations — on the current label, single-dose syringes 0.25, 0.5, 1, 1.7, 2.4 mg 5 May 2026
Wegovy FlexTouch, single-patient-use pen, 4 doses 2.4 mg per dose (9.6 mg/3 mL) 18 June 2026

Orange Book product file dated 11 September 2026; device names from section 3 of the June 2026 label. The Orange Book does not name the device for the 5 May 2026 listings; the label's only presentations at those strengths other than the original pens are the single-dose syringes.

Counted the way the label groups them — single-dose pen, HD pen, single-dose syringe, FlexTouch pen and tablet — that is five forms, and sixteen product listings in FDA's register. The FlexTouch is Wegovy's first multi-dose pen and, at a single 2.4 mg strength, is a maintenance-dose device. What the tablets demand each morning — the empty stomach, the water limit, the 30-minute wait — is on the Ozempic pill, whose tablets share the formulation, and on oral GLP-1s.

The record behind the label, action by action

The four uses and five forms above arrived one FDA action at a time. Drugs@FDA lists every approval action on the injection's application, NDA 215256; read on 17 November 2026, there are sixteen:

Kind of action Count Dates
Original approval 1 4 June 2021
Efficacy supplements (new uses, populations or strengths) 7 23 Dec 2022 · 21 Jul 2023 · 8 Mar 2024 · 27 Nov 2024 · 15 Aug 2025 · 21 Nov 2025 · 19 Mar 2026
Labelling supplements 6 24 Aug 2022 · 14 Feb 2023 · 1 Nov 2024 · 14 Oct 2025 · 29 Jan 2026 · 25 Feb 2026
Manufacturing supplements 2 5 May 2026 · 18 June 2026

Three of the efficacy dates match the uses in the first table (children, heart risk, MASH). The 19 March 2026 efficacy approval falls on the day the 7.2 mg HD pen entered the Orange Book, and the two manufacturing approvals fall on the days the syringes (5 May) and the FlexTouch pen (18 June) were listed. Drugs@FDA's extract does not say what the other efficacy supplements (July 2023, November 2024, November 2025) changed, so this page does not guess. The tablet application, NDA 218316, has five labelling supplements, the last also on 18 June 2026.

The label itself has been republished often. DailyMed holds 19 versions of the combined injection-and-tablet label; six were published in the first half of 2026 alone (6 January to 30 June), and version 19 of 30 June 2026 was still the current one on 17 November 2026. Anyone quoting "the Wegovy label" from an older copy may be quoting text that has since changed — a repackager's copy still on openFDA, effective April 2024, lists no MASH use and no tablets.

The same molecule as Ozempic: why two brands exist

Ozempic was first approved in December 2017 for type 2 diabetes; the Wegovy label's "Initial U.S. Approval: 2017" refers to semaglutide itself, not to the Wegovy brand. Wegovy arrived in 2021 under a separate application for weight management, at higher maintenance strengths. The split matters in practice because insurance coverage and Medicare law follow the approved use, not the molecule: the same semaglutide can be payable under one label and excluded under the other. That mechanism is on GLP-1 insurance coverage, and the two brands side by side on Wegovy vs Ozempic. The label also states that Wegovy should not be used with other semaglutide products or any other GLP-1 drug.

The warnings, in one paragraph

The box at the top of the label concerns thyroid C-cell tumours: semaglutide caused them in rats and mice, and the label says nobody yet knows whether that carries over to people. Because of it, anyone with medullary thyroid carcinoma or the MEN 2 syndrome in their own or their family's history is excluded, as is anyone who has had a serious allergic reaction to the drug or its ingredients. Below the box, the label's warnings run through pancreatitis, gallbladder problems, low blood sugar when paired with insulin or a sulfonylurea, kidney damage after fluid loss, severe stomach and bowel reactions, eye complications in people with diabetes, a faster heart rate and suicidal thoughts. Stomach and bowel symptoms top the list of common reactions. The full record is on Wegovy side effects. Whether any of this applies to a particular person is for the prescriber.

How people get it

Wegovy is prescription-only. Novo Nordisk's self-pay prices, its savings offer and its own pharmacy are documented on what Wegovy costs, the Wegovy savings card and NovoCare Pharmacy; Medicare beneficiaries have a separate $50-a-month route, the Medicare GLP-1 Bridge.

Sources

Wegovy prescribing information (injection and tablets), revised 06/2026, DailyMed set ee06186f-2aa3-4990-a760-757579d8f77b · Drugs@FDA application records for NDA 215256 and NDA 218316 via openFDA · FDA approval letters for NDA 215256 supplements 5 (2022-12-23), 11 (2024-03-08) and 24 (2025-08-15) · FDA Orange Book product file dated 11 September 2026. All read 4 October 2026. Drugs@FDA submission lists for NDA 215256 and NDA 218316 (openFDA), DailyMed version history for set ee06186f-2aa3-4990-a760-757579d8f77b, and the openFDA label record f5e548d0-cc79-4c34-a3f5-e20a5b8b6564 (A-S Medication Solutions, effective 23 April 2024) read 17 November 2026.

Frequently asked questions

What is Wegovy?

Novo Nordisk's weight-management brand of semaglutide, sold as weekly injections and as daily tablets. Its injection label covers four uses: long-term weight management for adults, weight management for 12- to 17-year-olds with obesity, cutting the chance of a heart attack, stroke or heart-related death in adults who already have heart disease and carry excess weight, and a scarring form of fatty-liver disease (MASH). The tablets carry only the adult weight and heart uses.

How does Wegovy work?

According to its label, semaglutide binds to and activates the GLP-1 receptor, the target of the body's own GLP-1, a hormone the body itself uses to regulate appetite and food intake. The receptor is found in brain areas that regulate appetite. The label states that how it lowers cardiovascular risk has not been established and how it works in MASH is not fully understood.

Who makes Wegovy?

Novo Nordisk, the Danish company that also makes Ozempic and Rybelsus. Wegovy's US applications are held by Novo Nordisk, and the self-pay and savings programmes run through Novo's NovoCare site and NovoCare Pharmacy.

Is Wegovy the same as Ozempic?

Same molecule, different brand. Both contain semaglutide from Novo Nordisk, but Ozempic is approved for type 2 diabetes and related heart and kidney risks, while Wegovy is approved for weight management and its own cardiovascular and liver uses, with different strengths and a different maximum dose. Insurance treats them differently because of those labels. The comparison is on our Wegovy vs Ozempic page.

What forms does Wegovy come in?

Five kinds of presentation are on the current label and in FDA's register: single-dose pens from 0.25 mg to 2.4 mg, the 7.2 mg Wegovy HD pen, single-dose syringes at 0.25 to 2.4 mg, a four-dose Wegovy FlexTouch pen holding 9.6 mg, and once-daily tablets at 1.5, 4, 9 and 25 mg. The tablets are approved for fewer uses than the injection.

What is Wegovy not approved for?

Blood-sugar control in type 2 diabetes is not among its uses — that sits on Ozempic's label — and its label advises against pairing it with any other semaglutide brand or another GLP-1 drug. The tablet form has no approval for under-18s or for MASH. The label rules it out entirely for people whose own or family history includes medullary thyroid carcinoma or the MEN 2 syndrome.